The AHEPA University General Hospital, also known as AHEPA Hospital, is considered one of the biggest hospitals in Greece, based in Thessaloniki. Covers 680 beds and all the spectrum of medical and surgical specialities of medicine as well as the psychiatric sector.

There are 680 beds in University General Hospital of Thessaloniki AHEPA.

During the past decade, University General Hospital of Thessaloniki AHEPA conducted 44 clinical trials. In the 10-year time frame, 44 clinical trials started and 18 clinical trials were completed, i.e. on average, 40.9% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 15 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University General Hospital of Thessaloniki AHEPA" #1 sponsor was "Aristotle University Of Thessaloniki" with 11 trials, followed by "Boehringer Ingelheim" with 8 trials sponsored, "Hellenic Institute for the Study of Sepsis" with 5 trials sponsored, "Bayer" with 4 trials sponsored and "Eli Lilly and Company" with 4 trials sponsored. Other sponsors include 22 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University General Hospital of Thessaloniki AHEPA" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "University of Athens" with 2 trials as a collaborator, "AHEPA University Hospital" with 1 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator and "Athens General Hospital Hippokrateio" with 1 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "University General Hospital of Thessaloniki AHEPA" are "COVID-19" (5 trials), "Heart Failure" (4 trials), "Corona Virus Infection" (3 trials), "Diabetes Mellitus" (3 trials) and "Hypertension" (3 trials). Many other conditions were trialed in "University General Hospital of Thessaloniki AHEPA" in a lesser frequency.

Most popular intervention types in "University General Hospital of Thessaloniki AHEPA" are "Drug" (40 trials), "Device" (5 trials), "Other" (5 trials), "Procedure" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Anakinra" (2 trials), "Empagliflozin" (2 trials), "Sham Procedure" (2 trials) and "Symplicity Spyral™ multi-electrode renal denervation system" (2 trials). Other intervention names were less common.

The vast majority of trials in "University General Hospital of Thessaloniki AHEPA" are 58 trials for "All" genders.

Currently, there are NaN active trials in "University General Hospital of Thessaloniki AHEPA". undefined are not yet recruiting, 5 are recruiting, 8 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 39 completed trials in University General Hospital of Thessaloniki AHEPA, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in University General Hospital of Thessaloniki AHEPA, 3 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 16 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 7 trials that are defined as “Not Applicable".